HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 04, April 2018 – Digestive health in the 21st century - Trust your guts       » Food wasted in China could feed 30-50 million       » Chinese scientists analyze human brain's "CPU"       » $150,000 fundraiser launched to sequence South Asian genomes       » Green tea-based drug carriers improve cancer treatment       » Scientists grow liver cancer cells in lab      

BIOBOARD - TAIWAN

Peptide Nasal Spray to Delay Onset of Alzheimer’s disease

Dr. Rita P.-Y. Chen, an Associate Research Fellow at the Institute of Biological Chemistry along with Dr. Pang-hsien Tu, a former Assistant Research Fellow at the Institute of Biomedical Sciences, and their research teams recently found that a modified short peptide delays the onset of Alzheimer’s disease when delivered in the form of a nasal drop in a mouse model. The research was published in EMBO Molecular Medicine on March 29th, 2017.

Dr. Chen, Dr. Tu and colleagues designed a peptide, R8-Aβ(25-35)-PEI, which was able to enter into the brain through the nose and reduce accumulation of Aβ peptide which is widely believed to be a critical determinant of Alzheimer’s disease. Using fluorescence-labeling, the team found that the peptide reached a maximum in the brain at six hours after intranasal administration and the nose-to-brain penetration efficiency was more than 17%. Results from transgenic mouse studies indicated that daily intranasal administration of 6 micrograms of R8-Aβ(25-35)-PEI for 4 months (6 days/week) significantly reduced Aβ amyloid accumulation in the brain and ameliorated memory deficits in APP/PS1 double transgenic mice, a mouse model that expresses mutated amyloid precursor protein and β-secretase, which greatly increase the production of Aβ peptides, especially Aβ42, and therefore mimics Alzheimer’s disease.

Alzheimer’s disease is characterized by neurofibrillary tangles and senile amyloid plaques in the brain. The amyloid plaques are mainly composed of Aβpeptides which are produced in the brain during the catabolism of a protein named amyloid precursor protein (APP). Under normal conditions, Aβ can be degraded by various Aβ-degrading enzymes. However, if the rate of Aβ production exceeds the rate of Aβ degradation, Aβ can accumulate in the brain and form amyloid plaques resulting in the death of neurons. The formation and deposition of amyloid plaques might occur 20 years before clinical onset, hence Aβ is one of the most important targets for the prevention of Alzheimer’s disease.

The number of patients diagnosed with Alzheimer’s disease has significantly increased in recent years due in part to aging populations. Since the average life expectancy after diagnosis with Alzheimer’s varies from 4 to 20 years, medical and non-medical care for Alzheimer’s patients can lead to significant economic and social burdens.

So far, no observable side-effects of the peptide treatment have been observed in the mice, and the rationale of peptide design may also be feasibly applied to other neurodegenerative disorders.

The full research article entitled “An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice” is available at the EMBO Molecular Medicine website at: https://embomolmed.embopress.org/content/early/2017/03/28/emmm.201606666.long

The complete list of authors is: Yu-Sung Cheng, Zih-ten Chen, Tai-Yan Liao, Chen Lin, Howard C.-H. Shen, Ya-Han Wang, Chi-Wei Chang, Ren-Shyan Liu, Rita P.-Y. Chen*, and Pang-hsien Tu*.

Source: Academia Sinica

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy